UPDATE: Jefferies Raises PT to $32 on Pacira Pharmaceuticals on Exparel Launch Momentum
March 11, 2013 at 11:09 AM EDT
Jefferies maintained Pacira Pharmaceuticals (NASDAQ: PCRX ) with a Buy rating and raised the price target from $24.00 to $32.00. Jefferies commented, "PCRX is heading into its 4th Q of Exparel launch with strong momentum. Exparel access and uptake continue to ramp (volume growth through end'12 looked parabolic) and PCRX
